References

Abou Ali, Mohamad, Fadi Dornaika, and Jinan Charafeddine. 2026. “Agentic AI: A Comprehensive Survey of Architectures, Applications, and Future Directions.” Artificial Intelligence Review 59: 11. https://doi.org/10.1007/s10462-025-11422-4.

Agresti, Alan. 2010. Analysis of Ordinal Categorical Data. 2nd ed. Wiley. https://doi.org/10.1002/9780470594001.

Almirall, Daniel, Inbal Nahum-Shani, Nancy E. Sherwood, and Susan A. Murphy. 2014. “Introduction to SMART Designs for the Development of Adaptive Interventions: With Application to Weight Loss Research.” Translational Behavioral Medicine 4 (3): 260–74. https://doi.org/10.1007/s13142-014-0265-0.

Amershi, Saleema, Dan Weld, Mihaela Vorvoreanu, Adam Fourney, Besmira Nushi, Penny Collisson, Jina Suh, et al. 2019. “Guidelines for Human-AI Interaction.” In Proceedings of the 2019 CHI Conference on Human Factors in Computing Systems, 1–13. https://doi.org/10.1145/3290605.3300233.

Anagnostopoulos, Chris, David Champagne, Thomas Devenyns, Alex Devereson, and Heikki Tarkkila. 2023. “How Artificial Intelligence Can Power Clinical Development.” McKinsey & Company. https://www.mckinsey.com/industries/life-sciences/our-insights/how-artificial-intelligence-can-power-clinical-development.

Andhalkar, Niranjan. 2025. “Phase-by-Phase Clinical Trial Costs Guide for Sponsors.” ProRelix Research blog. https://prorelixresearch.com/phase-by-phase-clinical-trial-costs-guide/.

Angus, Derek C., Scott Berry, Roger J. Lewis, Farah Al-Beidh, Yaseen Arabi, Wilma van Bentum-Puijk, Zahra Bhimani, et al. 2020. “The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-Acquired Pneumonia) Study: Rationale and Design.” Annals of the American Thoracic Society 17 (7): 879–91. https://doi.org/10.1513/AnnalsATS.202003-192SD.

Anthropic. 2025. “Model Context Protocol: Introduction.” https://modelcontextprotocol.io/docs/getting-started/intro.

Armitage, Peter. 1954. “Sequential Tests in Prophylactic and Therapeutic Trials.” Quarterly Journal of Medicine 23 (91): 255–74.

———. 1960. Sequential Medical Trials. Oxford: Blackwell Scientific Publications.

Association of Clinical Research Organizations. 2025. “2025 Risk-Based Quality Management (RBQM) Summary Report.” https://www.acrohealth.org/wp-content/uploads/2025/06/ACRO_2025-RBQM-Report_Final-062425.pdf.

Atkinson, A. C. 2002. “The Comparison of Designs for Sequential Clinical Trials with Covariate Information.” Journal of the Royal Statistical Society: Series A 165 (2): 349–73. https://doi.org/10.1111/1467-985X.00564.

ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Patrick R. Lawler, Ewan C. Goligher, Jeffrey S. Berger, et al. 2021. “Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.” New England Journal of Medicine 385 (9): 790–802. https://doi.org/10.1056/NEJMoa2105911.

Avorn, Jerry. 2015. “The $2.6 Billion Pill — Methodologic and Policy Considerations.” New England Journal of Medicine 372 (20): 1877–79. https://doi.org/10.1056/NEJMp1500848.

Babb, James, Andre Rogatko, and Shelemyahu Zacks. 1998. “Cancer Phase I Clinical Trials: Efficient Dose Escalation with Overdose Control.” Statistics in Medicine 17 (10): 1103–20. https://doi.org/10.1002/(SICI)1097-0258(19980530)17:10<1103::AID-SIM793>3.0.CO;2-9.

Baiocchi, Michael, Jing Cheng, and Dylan S. Small. 2014. “Instrumental Variable Methods for Causal Inference.” Statistics in Medicine 33 (13): 2297–2340. https://doi.org/10.1002/sim.6128.

Ballentine, Carol. 1981. “Taste of Raspberries, Taste of Death: The 1937 Elixir Sulfanilamide Incident.” FDA Consumer. https://www.fda.gov/files/about%20fda/published/The-Sulfanilamide-Disaster.pdf.

Bartlett, Robert H., Donald W. Roloff, Robert G. Cornell, Arthur F. Andrews, Patrick W. Dillon, and Joseph B. Zwischenberger. 1985. “Extracorporeal Circulation in Neonatal Respiratory Failure: A Prospective Randomized Study.” Pediatrics 76 (4): 479–87. https://doi.org/10.1542/peds.76.4.479.

Beal, Kristy, Juliette Dean, James Chen, Elena Dragaon, Ann Saulino, and Charles D. Collard. 2004. “Budget Negotiation for Industry-Sponsored Clinical Trials.” Anesthesia & Analgesia 99 (1): 173–76. https://doi.org/10.1213/01.ANE.0000122633.97424.76.

Bender, Emily M., Timnit Gebru, Angelina McMillan-Major, and Shmargaret Shmitchell. 2021. “On the Dangers of Stochastic Parrots: Can Language Models Be Too Big?” In Proceedings of the 2021 ACM Conference on Fairness, Accountability, and Transparency, 610–23. https://doi.org/10.1145/3442188.3445922.

Berkeley Artificial Intelligence Research. 2024. “The Shift from Models to Compound AI Systems.” https://bair.berkeley.edu/blog/2024/02/18/compound-ai-systems/.

Berry, Donald A. 1989. “Monitoring Accumulating Data in a Clinical Trial.” Biometrics 45 (4): 1197–1211. https://doi.org/10.2307/2531771.

———. 2012. “Adaptive Clinical Trials in Oncology.” Nature Reviews Clinical Oncology 9 (4): 199–207. https://doi.org/10.1038/nrclinonc.2011.165.

———. 2025. “Adaptive Bayesian Clinical Trials: The Past, Present, and Future of Clinical Research.” Journal of Clinical Medicine 14 (15): 5267. https://doi.org/10.3390/jcm14155267.

Berry, Scott M., Bradley P. Carlin, J. Jack Lee, and Peter Müller. 2010. Bayesian Adaptive Methods for Clinical Trials. Chapman & Hall/CRC Biostatistics Series. Boca Raton, FL: CRC Press. https://doi.org/10.1201/EBK1439825488.

Biotechnology Innovation Organization, QLS Advisors, and Informa Pharma Intelligence. 2021. “Clinical Development Success Rates 2011-2020.” https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf.

Bor, Jacob, Ellen Moscoe, Portia Mutevedzi, Marie-Louise Newell, and Till Bärnighausen. 2014. “Regression Discontinuity Designs in Epidemiology: Causal Inference Without Randomized Trials.” Epidemiology 25 (5): 729–37. https://doi.org/10.1097/EDE.0000000000000138.

Bretz, Frank, Jose C. Pinheiro, and Michael Branson. 2005. “Combining Multiple Comparisons and Modeling Techniques in Dose-Response Studies.” Biometrics 61 (3): 738–48. https://doi.org/10.1111/j.1541-0420.2005.00344.x.

Bronner, Denise. 2024. “Why Site-CRO Relationships Are so Strained, and How to Fix Them.” Clinical Leader, guest column. https://www.clinicalleader.com/doc/why-site-cro-relationships-are-so-strained-and-how-to-fix-them-0001.

Budd Haeberlein, Samantha, Paul S. Aisen, Frederik Barkhof, Spyridon Chalkias, Tianle Chen, Sandra Cohen, Gary Dent, et al. 2022. “Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease.” Journal of Prevention of Alzheimer’s Disease 9 (2): 197–210. https://doi.org/10.14283/jpad.2022.30.

Cappello, Franck, Sandeep Madireddy, Robert Underwood, Neil Getty, Nicholas Lee-Ping Chia, Nesar Ramachandra, et al. 2025. “EAIRA: Establishing a Methodology for Evaluating AI Models as Scientific Research Assistants.” arXiv Preprint arXiv:2502.20309. https://arxiv.org/abs/2502.20309.

Cemri, Mert, Melissa Z. Pan, Shuyi Yang, Lakshya A. Agrawal, Bhavya Chopra, Rishabh Tiwari, Kurt Keutzer, et al. 2025. “Why Do Multi-Agent LLM Systems Fail?” arXiv Preprint arXiv:2503.13657. https://arxiv.org/abs/2503.13657.

Chan, An-Wen, Isabelle Boutron, Sally Hopewell, David Moher, Kenneth F. Schulz, Gary S. Collins, et al. 2025. “SPIRIT 2025 Statement: Updated Guideline for Protocols of Randomised Trials.” BMJ 389: e081477. https://doi.org/10.1136/bmj-2024-081477.

Chan, Jun Shern, Neil Chowdhury, Oliver Jaffe, James Aung, Dane Sherburn, Evan Mays, Giulio Starace, et al. 2024. “MLE-Bench: Evaluating Machine Learning Agents on Machine Learning Engineering.” arXiv Preprint arXiv:2410.07095. https://arxiv.org/abs/2410.07095.

Cheng, Yuheng, Ceyao Zhang, Zhengwen Zhang, Xiangrui Meng, Sirui Hong, Wenhao Li, Zihao Wang, et al. 2024. “Exploring Large Language Model Based Intelligent Agents: Definitions, Methods, and Prospects.” arXiv Preprint arXiv:2401.03428. https://arxiv.org/abs/2401.03428.

Clinical Data Interchange Standards Consortium. 2024. “CDISC Foundational Standards: SDTM, ADaM, and CDASH.” https://www.cdisc.org/standards/foundational.

Clinical Leader. 2024. “Best Practices for Randomization and Trial Supply Management (RTSM).” https://www.clinicalleader.com/doc/best-practices-for-randomization-and-trial-supply-management-rtsm-0001.

Coart, Elisabeth, Perrine Bamps, Emmanuel Quinaux, Geneviève Sturbois, Everardo D. Saad, Tomasz Burzykowski, and Marc Buyse. 2023. “Minimization in Randomized Clinical Trials.” Statistics in Medicine 42 (28): 5285–5311. https://doi.org/10.1002/sim.9916.

Cohen, Lauren W., Rowena J. Dolor, Mark Weiner, Nadine Zemon, Charles Bailey, Thomas Carton, Erika Cottrell, et al. 2026. “PCORnet: 10 Years of Research Innovation.” Medical Care 64: S185–90. https://doi.org/10.1097/MLR.0000000000002269.

Collins, Gary S. et al. 2024. “TRIPOD+AI Statement: Updated Guidance for Reporting Clinical Prediction Models That Use Regression or Machine Learning Methods.” BMJ 385: e078378. https://www.bmj.com/content/385/bmj-2023-078378.

Council for International Organizations of Medical Sciences (CIOMS). 2016. International Ethical Guidelines for Health-Related Research Involving Humans. Fourth. Geneva: CIOMS. https://cioms.ch/publications/product/international-ethical-guidelines-for-health-related-research-involving-humans/.

Cox, D. R. 1958. Planning of Experiments. New York: John Wiley & Sons.

———. 1972. “Regression Models and Life-Tables.” Journal of the Royal Statistical Society: Series B (Methodological) 34 (2): 187–220. https://doi.org/10.1111/j.2517-6161.1972.tb00899.x.

———. 2009. “Randomization in the Design of Experiments.” International Statistical Review 77 (3): 415–29. https://doi.org/10.1111/j.1751-5823.2009.00084.x.

Dahabreh, Issa J., Sarah E. Robertson, Jon A. Steingrimsson, Elizabeth A. Stuart, and Miguel A. Hernan. 2020. “Extending Inferences from a Randomized Trial to a New Target Population.” Statistics in Medicine 39 (14): 1999–2014. https://doi.org/10.1002/sim.8426.

Dahabreh, Issa J., Sarah E. Robertson, Eric J. Tchetgen Tchetgen, Elizabeth A. Stuart, and Miguel A. Hernan. 2019. “Generalizing Causal Inferences from Individuals in Randomized Trials to All Trial-Eligible Individuals.” Biometrics 75 (2): 685–94. https://doi.org/10.1111/biom.13009.

Davis, Joshua S., John Turnidge, and Steven Y. C. Tong. 2018. “A Large Retrospective Cohort Study of Cefazolin Compared with Flucloxacillin for Methicillin-Susceptible Staphylococcus aureus Bacteraemia.” International Journal of Antimicrobial Agents 52 (2): 297–300. https://doi.org/10.1016/j.ijantimicag.2018.02.013.

Deloitte Centre for Health Solutions. 2025. “Be Brave, Be Bold: Measuring the Return from Pharmaceutical Innovation.” https://www.deloitte.com/content/dam/assets-shared/docs/industries/life-sciences-health-care/2025/deloitte-measuring-return-from-pharmaceutical-innovation-2025.pdf.

———. 2026. “Navigating the GLP-1 Boom: Measuring the Return from Pharmaceutical Innovation.” https://www.deloitte.com/content/dam/assets-shared/docs/industries/life-sciences-health-care/2026/measuring-the-return-from-pharmaceutical-innovation.pdf.

DeTora, Lisa M., Dikran Toroser, Angela Sykes, Christine Vanderlinden, Fiona J. Plunkett, Trevor Lane, Eline Hanekamp, et al. 2022. “Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update.” Annals of Internal Medicine 175 (9): 1298–1304. https://doi.org/10.7326/M22-1460.

Dickerman, Barbra A., Hanna Gerlovin, Arin L. Madenci, Katherine E. Kurgansky, Brian R. Ferolito, Mariantonia Figueroa Munõz, David R. Gagnon, et al. 2022. “Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans.” New England Journal of Medicine 386 (2): 105–15. https://doi.org/10.1056/NEJMoa2115463.

DiMasi, Joseph A., Henry G. Grabowski, and Ronald W. Hansen. 2016. “Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs.” Journal of Health Economics 47: 20–33. https://doi.org/10.1016/j.jhealeco.2016.01.012.

Douze, Matthijs, Alexandr Guzhva, Chengqi Deng, Jeff Johnson, Gergely Szilvasy, Pierre-Emmanuel Mazaré, Maria Lomeli, Lucas Hosseini, and Hervé Jégou. 2024. “The Faiss Library.” arXiv Preprint arXiv:2401.08281. https://arxiv.org/abs/2401.08281.

Duke Center for Virtual Imaging Trials. 2024. “Virtual Imaging Trials in Medicine 2024 Summit.” https://cvit.duke.edu/vitm24/.

Dyck, Christopher H. van, Chad J. Swanson, Paul Aisen, Randall J. Bateman, Christopher Chen, Michelle Gee, Michio Kanekiyo, et al. 2023. “Lecanemab in Early Alzheimer’s Disease.” New England Journal of Medicine 388 (1): 9–21. https://doi.org/10.1056/NEJMoa2212948.

Echt, Debra S., Philip R. Liebson, L. Brent Mitchell, Robert W. Peters, Dulce Obias-Manno, Allan H. Barker, Daniel Arensberg, et al. 1991. “Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo: The Cardiac Arrhythmia Suppression Trial.” New England Journal of Medicine 324 (12): 781–88. https://doi.org/10.1056/NEJM199103213241201.

Efron, Bradley. 1971. “Forcing a Sequential Experiment to Be Balanced.” Biometrika 58 (3): 403–17. https://doi.org/10.1093/biomet/58.3.403.

EMA Committee for Medicinal Products for Human Use (CHMP). 2014. “Qualification Opinion of MCP-Mod as an Efficient Statistical Methodology for Model-Based Design and Analysis of Phase II Dose Finding Studies Under Model Uncertainty.” European Medicines Agency. https://www.ema.europa.eu/en/documents/scientific-guideline/qualification-opinion-mcp-mod-efficient-statistical-methodology-model-based-design-analysis-phase-ii_en.pdf.

Emanuel, Ezekiel J., David Wendler, and Christine Grady. 2000. “What Makes Clinical Research Ethical?” JAMA 283 (20): 2701–11. https://doi.org/10.1001/jama.283.20.2701.

Epperson, Will, Gagan Bansal, Victor Dibia, Adam Fourney, Jack Gerrits, Erkang Zhu, and Saleema Amershi. 2025. “Interactive Debugging and Steering of Multi-Agent AI Systems.” arXiv Preprint arXiv:2503.02068. https://arxiv.org/abs/2503.02068.

Erlinge, David. 2021. “Registry-Based Randomized Clinical Trials in Cardiology: Opportunities and Challenges.” REC: Interventional Cardiology 3: 157–60. https://doi.org/10.24875/RECICE.M21000205.

Erlinge, David, Sasha Koul, Peter Eriksson, Fredrik Scherstén, Elmir Omerovic, Rikard Linder, Olof Petter Östlund, Lars Wallentin, Ole Fröbert, and Stefan James. 2016. “Bivalirudin Versus Heparin in Non-ST and ST-Segment Elevation Myocardial Infarction: A Registry-Based Randomized Clinical Trial in the SWEDEHEART Registry (the VALIDATE-SWEDEHEART Trial).” American Heart Journal 175: 36–46. https://doi.org/10.1016/j.ahj.2016.02.007.

Erlinge, David, Elmir Omerovic, Ole Fröbert, Rikard Linder, Mikael Danielewicz, Mehmet Hamid, Eva Swahn, et al. 2017. “Bivalirudin Versus Heparin Monotherapy in Myocardial Infarction.” New England Journal of Medicine 377 (12): 1132–42. https://doi.org/10.1056/NEJMoa1706443.

European Commission. 2011. “EudraLex Volume 4, EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Annex 11: Computerised Systems.” https://health.ec.europa.eu/document/download/e63bde49-af31-4d1d-8a2e-1f3f8e5f6d1c_en.

European Medicines Agency. 2006. “Guideline on Clinical Trials in Small Populations.” https://www.ema.europa.eu/en/clinical-trials-small-populations-scientific-guideline.

———. 2014a. “Assessment Report: Trulicity (Dulaglutide).” EMA/CHMP/524604/2014, Procedure No. EMEA/H/C/002825/0000. https://www.ema.europa.eu/en/documents/assessment-report/trulicity-epar-public-assessment-report_en.pdf.

———. 2014b. “European Medicines Agency Policy on Publication of Clinical Data for Medicinal Products for Human Use (Policy 0070).” https://www.ema.europa.eu/en/human-regulatory-overview/marketing-authorisation/clinical-data-publication.

———. 2017a. “Guideline on Good Pharmacovigilance Practices (GVP) Module IX Addendum I: Methodological Aspects of Signal Detection from Spontaneous Reports of Suspected Adverse Reactions.” https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-ix-addendum-i-methodological-aspects-signal-detection-spontaneous-reports-suspected-adverse-reactions_en.pdf.

———. 2017b. “Guideline on Strategies to Identify and Mitigate Risks for First-in-Human and Early Clinical Trials with Investigational Medicinal Products.” EMEA/CHMP/SWP/28367/07 Rev. 1. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-strategies-identify-mitigate-risks-first-human-early-clinical-trials-investigational_en.pdf.

———. 2022. “Clinical Trials Regulation (EU) No 536/2014 and Clinical Trials Information System (CTIS).” https://www.ema.europa.eu/en/human-regulatory/research-development/clinical-trials/clinical-trials-regulation.

———. 2023. “Guideline on Computerised Systems and Electronic Data in Clinical Trials.” https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-computerised-systems-and-electronic-data-clinical-trials_en.pdf.

———. 2024a. “ICH E6(R3) Good Clinical Practice Guidelines.” https://www.ema.europa.eu/en/ich-e6-good-clinical-practice-scientific-guideline.

———. 2024b. “Reflection Paper on the Use of Artificial Intelligence (AI) in the Lifecycle of Medicinal Products.” https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-use-artificial-intelligence-ai-medicinal-product-lifecycle_en.pdf.

———. 2025. “Draft Concept Paper on the Development of a Reflection Paper on the Use of External Controls for Evidence Generation in Regulatory Decision-Making.” https://www.ema.europa.eu/en/documents/scientific-guideline/draft-concept-paper-development-reflection-paper-use-external-controls-evidence-generation-regulatory-decision-making_en.pdf.

———. 2026. “DARWIN EU Data Partners Onboarded in Year I, II, III, IV, and V.” https://www.ema.europa.eu/en/documents/other/darwin-eu-data-partners-onboarded-phases-i-ii-iii_en.pdf.

European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). 2022. “Qualification Opinion for Prognostic Covariate Adjustment (PROCOVA).” European Medicines Agency. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/qualification-opinion-prognostic-covariate-adjustment-procovatm_en.pdf.

European Parliament and Council of the European Union. 2004. “Regulation (EC) No 726/2004 Laying down Community Procedures for the Authorisation and Supervision of Medicinal Products for Human and Veterinary Use and Establishing a European Medicines Agency.” https://eur-lex.europa.eu/eli/reg/2004/726/oj/eng.

———. 2014. “Regulation (EU) No 536/2014 on Clinical Trials on Medicinal Products for Human Use, and Repealing Directive 2001/20/EC.” https://eur-lex.europa.eu/eli/reg/2014/536/oj/eng.

———. 2024. “Regulation (EU) 2024/1689 Laying down Harmonised Rules on Artificial Intelligence (Artificial Intelligence Act).” https://eur-lex.europa.eu/eli/reg/2024/1689/oj/eng.

———. 2026. “Regulation (EU) 2026/1744 Amending Regulations (EU) 2024/1689, (EU) 2018/1139 and (EU) 2023/1230 as Regards the Simplification of the Implementation of Harmonised Rules on Artificial Intelligence (Digital Omnibus on AI).” http://data.europa.eu/eli/reg/2026/1744/oj.

Evans, Scott R., and Dean Follmann. 2016. “Using Outcomes to Analyze Patients Rather Than Patients to Analyze Outcomes: A Step Toward Pragmatism in Benefit:risk Evaluation.” Statistics in Biopharmaceutical Research 8 (4): 386–93. https://doi.org/10.1080/19466315.2016.1207561.

Evans, Scott R., David Rubin, Dean Follmann, Gene Pennello, W. Charles Huskins, John H. Powers, Jerry Rhorer, et al. 2015. “Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR).” Clinical Infectious Diseases 61 (5): 800–806. https://doi.org/10.1093/cid/civ495.

Faro Health. 2024. “Faro Health: AI-Powered Protocol Design.” https://farohealth.com.

Fine, Jason P., and Robert J. Gray. 1999. “A Proportional Hazards Model for the Subdistribution of a Competing Risk.” Journal of the American Statistical Association 94 (446): 496–509. https://doi.org/10.1080/01621459.1999.10474144.

Fischl, Margaret A., Douglas D. Richman, Michael H. Grieco, Michael S. Gottlieb, Paul A. Volberding, Oscar L. Laskin, John M. Leedom, et al. 1987. “The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex: A Double-Blind, Placebo-Controlled Trial.” New England Journal of Medicine 317 (4): 185–91. https://doi.org/10.1056/NEJM198707233170401.

Fisher, Charles K. 2024. “US FDA Comments on Unlearn’s PROCOVA Methodology.” Unlearn.AI blog. https://www.unlearn.ai/blog/us-fda-comments-on-unlearns-procova-methodology.

Fortrea Holdings Inc. 2026. “Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance.” https://ir.fortrea.com/news-releases/news-release-details/fortrea-reports-fourth-quarter-and-full-year-2025-results-issues.

Fortune Business Insights. 2024. “AI in Clinical Trials Market Size, Share & Industry Analysis.” https://www.fortunebusinessinsights.com/ai-in-clinical-trials-market-114081.

Freedman, Benjamin. 1987. “Equipoise and the Ethics of Clinical Research.” New England Journal of Medicine 317 (3): 141–45. https://doi.org/10.1056/NEJM198707163170304.

Friends of Cancer Research. 2023. “Considerations for Leveraging Real-World Endpoints in Oncology Drug Development.” https://friendsofcancerresearch.org/wp-content/uploads/Considerations_Leveraging_Real-World_Endpoints_Oncology.pdf.

Fröbert, Ole, Bo Lagerqvist, Göran K. Olivecrona, Elmir Omerovic, Thorarinn Gudnason, Michael Maeng, Mikael Aasa, et al. 2013. “Thrombus Aspiration During ST-Segment Elevation Myocardial Infarction.” New England Journal of Medicine 369 (17): 1587–97. https://doi.org/10.1056/NEJMoa1308789.

Garcia, Crystal J., Kevin Haynes, Sean D. Pokorney, Nancy D. Lin, Cheryl McMahill-Walraven, Vinit Nair, Lauren Parlett, et al. 2020. “Practical Challenges in the Conduct of Pragmatic Trials Embedded in Health Plans: Lessons of IMPACT-AFib, an FDA-Catalyst Trial.” Clinical Trials 17 (4): 360–67. https://doi.org/10.1177/1740774520928426.

Gebru, Timnit, Jamie Morgenstern, Briana Vecchione, Jennifer Wortman Vaughan, Hanna Wallach, Hal Daumé III, and Kate Crawford. 2021. “Datasheets for Datasets.” Communications of the ACM 64 (12): 86–92. https://doi.org/10.1145/3458723.

Getz, Kenneth A. 2008. “Is Investigative Site Feasibility Feasible?” Applied Clinical Trials. https://www.appliedclinicaltrialsonline.com/view/investigative-site-feasibility-feasible.

———. 2012. “Enrollment Performance: Weighing the ‘Facts’.” Applied Clinical Trials 21 (5). https://www.appliedclinicaltrialsonline.com/view/enrollment-performance-weighing-facts.

Getz, Kenneth A., Zachary P. Smith, and Marcy Kravet. 2023. “Protocol Design and Performance Benchmarks by Phase and by Oncology and Rare Disease Subgroups.” Therapeutic Innovation & Regulatory Science 57 (1): 49–56. https://doi.org/10.1007/s43441-022-00438-5.

Getz, Kenneth A., Zachary Smith, Emily Botto, Elisabeth Murphy, and Arnaud Dauchy. 2024. “New Benchmarks on Protocol Amendment Practices, Trends and Their Impact on Clinical Trial Performance.” Therapeutic Innovation & Regulatory Science 58 (3): 539–48. https://doi.org/10.1007/s43441-024-00622-9.

Getz, Kenneth A., Stella Stergiopoulos, Mary Short, Leon Surgeon, Randy Krauss, Sybrand Pretorius, Julian Desmond, and Derek Dunn. 2016. “The Impact of Protocol Amendments on Clinical Trial Performance and Cost.” Therapeutic Innovation & Regulatory Science 50 (4): 436–41. https://doi.org/10.1177/2168479016632271.

Glickman, Seth W., John G. McHutchison, Eric D. Peterson, Charles B. Cairns, Robert A. Harrington, Robert M. Califf, and Kevin A. Schulman. 2009. “Ethical and Scientific Implications of the Globalization of Clinical Research.” New England Journal of Medicine 360 (8): 816–23. https://doi.org/10.1056/NEJMsb0803929.

Goodman, Steven. 2008. “A Dirty Dozen: Twelve P-Value Misconceptions.” Seminars in Hematology 45 (3): 135–40. https://doi.org/10.1053/j.seminhematol.2008.04.003.

Grand View Research. 2025. “Clinical Trials Support Software Solutions Market Size, Share & Trends Analysis Report.” https://www.grandviewresearch.com/industry-analysis/clinical-trials-support-software-solutions-market-report.

———. 2026. “Healthcare Contract Research Organization Market Report, 2026-2033.” https://www.grandviewresearch.com/industry-analysis/healthcare-contract-research-outsourcing-market.

Granholm, Anders, Aksel Karl Georg Jensen, Theis Lange, Anders Perner, Morten Hylander Møller, and Benjamin Skov Kaas-Hansen. 2025. “Designing and Evaluating Bayesian Advanced Adaptive Randomised Clinical Trials: A Practical Guide.” Pharmaceutical Statistics 24 (6). https://doi.org/10.1002/pst.70042.

Grossi, Giuliana. 2025. “FDA Quietly Removes Draft Guidance on Diversity in Clinical Trials Following Executive Order on DEI.” The American Journal of Managed Care (AJMC). https://www.ajmc.com/view/fda-quietly-removes-draft-guidance-on-diversity-in-clinical-trials-following-executive-order-on-dei.

Gu, Ningzhou, Zizi Elsisi, Ryan Suk, and Meng Li. 2024. “Geographic Disparity in the Distribution of Cancer Clinical Trials in the United States and the Associated Factors.” Journal of Managed Care & Specialty Pharmacy 30 (4): 376–85. https://doi.org/10.18553/jmcp.2024.30.4.376.

H1. 2024. “H1: Healthcare Provider Intelligence Platform.” https://h1.co.

Han, Kiki, Franck Le Deu, Fangning Zhang, and Josie Zhou. 2021. “The Dawn of China Biopharma Innovation.” https://www.mckinsey.com/industries/life-sciences/our-insights/the-dawn-of-china-biopharma-innovation.

Harris Interactive. 2004. “Most Physicians Do Not Participate in Clinical Trials Because of Lack of Opportunity, Time, Personnel Support and Resources.” https://www.biospace.com/b-harris-interactive-b-release-most-physicians-do-not-participate-in-clinical-trials-because-of-lack-of-opportunity-time-personnel-support-and-r.

Health Level Seven International. 2024. “HL7 FHIR Bulk Data Access (Flat FHIR).” https://hl7.org/fhir/uv/bulkdata/.

Hernán, Miguel A., and James M. Robins. 2016. “Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available.” American Journal of Epidemiology 183 (8): 758–64. https://doi.org/10.1093/aje/kwv254.

Hobbs, Brian P., Bradley P. Carlin, Sumithra J. Mandrekar, and Daniel J. Sargent. 2011. “Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials.” Biometrics 67 (3): 1047–56. https://doi.org/10.1111/j.1541-0420.2011.01564.x.

Hripcsak, George, and David J. Albers. 2013. “Next-Generation Phenotyping of Electronic Health Records.” Journal of the American Medical Informatics Association 20 (1): 117–21. https://pmc.ncbi.nlm.nih.gov/articles/PMC3555337/.

Hripcsak, George, Jon D. Duke, Nigam H. Shah, Christian G. Reich, Vojtech Huser, Martijn J. Schuemie, Marc A. Suchard, et al. 2015. “Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers.” Studies in Health Technology and Informatics. https://pmc.ncbi.nlm.nih.gov/articles/PMC4815923/.

Hu, Feifang, and William F. Rosenberger. 2006. The Theory of Response-Adaptive Randomization in Clinical Trials. Hoboken, NJ: John Wiley & Sons. https://doi.org/10.1002/047005588X.

Hudson, Marie, Antonio Avina-Zubieta, Diane Lacaille, Sasha Bernatsky, Lisa Lix, and Sonia Jean. 2013. “The Validity of Administrative Data to Identify Hip Fractures Is High: A Systematic Review.” Journal of Clinical Epidemiology 66 (3): 278–85. https://doi.org/10.1016/j.jclinepi.2012.10.004.

Huey, Ryan W., Goldy C. George, Penny Phillips, Revenda White, Siqing Fu, Filip Janku, Daniel D. Karp, et al. 2021. “Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials.” The Oncologist 26 (7): 588–96. https://doi.org/10.1002/onco.13767.

Ibrahim, Joseph G., and Ming-Hui Chen. 2000. “Power Prior Distributions for Regression Models.” Statistical Science 15 (1): 46–60. https://doi.org/10.1214/ss/1009212673.

ICON plc. 2026. “Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025.” https://investor.iconplc.com/static-files/ce9930d9-1163-4cbe-907e-540cb4a46d01.

Industry Standard Research (ISR). 2025. “EDC Benchmarking and Market Dynamics (6th Edition).” https://isrreports.com/reports/2025-edc-benchmarking/.

International Council for Harmonisation. 1994a. “ICH Harmonised Tripartite Guideline: Clinical Safety Data Management: Definitions and Standards for Expedited Reporting E2A.” https://database.ich.org/sites/default/files/E2A_Guideline.pdf.

———. 1994b. “ICH Harmonised Tripartite Guideline: The Extent of Population Exposure to Assess Clinical Safety for Drugs Intended for Long-Term Treatment of Non-Life-Threatening Conditions E1.” https://database.ich.org/sites/default/files/E1_Guideline.pdf.

———. 1995. “ICH Harmonised Tripartite Guideline: Structure and Content of Clinical Study Reports E3.” https://database.ich.org/sites/default/files/E3_Guideline.pdf.

———. 1996. “ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6(R1).” https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e6-r1-guideline-good-clinical-practice_en.pdf.

———. 1998a. “ICH Harmonised Tripartite Guideline: Ethnic Factors in the Acceptability of Foreign Clinical Data E5(R1).” https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-5-r1-ethnic-factors-acceptability-foreign-clinical-data-step-5_en.pdf.

———. 1998b. “ICH Harmonised Tripartite Guideline: Statistical Principles for Clinical Trials E9.” https://database.ich.org/sites/default/files/E9_Guideline.pdf.

———. 2010. “ICH Harmonised Tripartite Guideline: Development Safety Update Report E2F.” https://database.ich.org/sites/default/files/E2F_Guideline.pdf.

———. 2013. “ICH E2B(R3): Electronic Transmission of Individual Case Safety Reports (ICSRs): Data Elements and Message Specification.” https://ich.org/page/e2br3-individual-case-safety-report-icsr-specification-and-related-files.

———. 2015. “ICH M8: Electronic Common Technical Document (eCTD), Version 4.0.” https://www.ich.org/page/ich-electronic-common-technical-document-ectd-v40.

———. 2016a. “ICH E6(R2): Integrated Addendum to ICH E6(R1) - Guideline for Good Clinical Practice.” https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf.

———. 2016b. “ICH M4: Organisation of the Common Technical Document for the Registration of Pharmaceuticals for Human Use.” https://www.ich.org/page/ctd.

———. 2017. “ICH Harmonised Guideline: General Principles for Planning and Design of Multi-Regional Clinical Trials E17.” https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-e17-general-principles-planning-and-design-multi-regional-clinical-trials-step-5-first-version_en.pdf.

———. 2019. “ICH E9(R1): Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials.” https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf.

———. 2021. “ICH E8(R1): General Considerations for Clinical Studies.” https://database.ich.org/sites/default/files/ICH_E8-R1_Guideline_Step4_2021_1006.pdf.

———. 2025a. “E20 Adaptive Designs for Clinical Trials.” https://www.ema.europa.eu/en/ich-e20-adaptive-designs-clinical-trials-scientific-guideline.

———. 2025b. “ICH E6(R3): Guideline for Good Clinical Practice (GCP).” https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf.

———. 2025c. “ICH M11: Clinical Electronic Structured Harmonised Protocol (CeSHarP).” https://database.ich.org/sites/default/files/ICH_Step4_M11_Final_Guideline_2025_1119.pdf.

IQVIA. 2024a. “Decentralized Clinical Trials Solutions.” https://www.iqvia.com/solutions/research-and-development/decentralized-trials.

———. 2024b. “IQVIA Intelligent eTMF.” https://www.iqvia.com/library/fact-sheets/iqvia-intelligent-etmf.

IQVIA Holdings Inc. 2026. “Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2025.” https://s201.q4cdn.com/580005511/files/doc_financials/2025/q4/IQV-2025-12-31-10K_Filed-with-exhibits.pdf.

IQVIA Institute for Human Data Science. 2024a. “Global Trends in R&D 2024: Activity, Productivity, and Enablers.” https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2024-activity-productivity-and-enablers.

———. 2024b. “Global Use of Medicines 2024: Outlook to 2028.” https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/the-global-use-of-medicines-2024-outlook-to-2028.

———. 2025. “Global Trends in R&D 2025.” https://iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025.

Jefferson, Tom, Mark Jones, Peter Doshi, Elizabeth A. Spencer, Igho Onakpoya, and Carl J. Heneghan. 2014. “Oseltamivir for Influenza in Adults and Children: Systematic Review of Clinical Study Reports and Summary of Regulatory Comments.” BMJ 348: g2545. https://doi.org/10.1136/bmj.g2545.

Jennison, Christopher, and Bruce W. Turnbull. 2000. Group Sequential Methods with Applications to Clinical Trials. Boca Raton, FL: Chapman & Hall/CRC.

———. 2015. “Adaptive Sample Size Modification in Clinical Trials: Start Small Then Ask for More?” Statistics in Medicine 34 (29): 3793–3810. https://doi.org/10.1002/sim.6575.

Junod, Suzanne White. 2008. “FDA and Clinical Drug Trials: A Short History.” U.S. Food and Drug Administration. https://www.fda.gov/media/110437/download.

Kaplan, E. L., and Paul Meier. 1958. “Nonparametric Estimation from Incomplete Observations.” Journal of the American Statistical Association 53 (282): 457–81. https://doi.org/10.1080/01621459.1958.10501452.

Kapoor, Sayash, Benedikt Stroebl, Zachary S. Siegel, Nitya Nadgir, and Arvind Narayanan. 2024. “AI Agents That Matter.” arXiv Preprint arXiv:2407.01502. https://arxiv.org/abs/2407.01502.

Khattab, Omar, Arnav Singhvi, Paridhi Maheshwari, Zhiyuan Zhang, Keshav Santhanam, Sri Vardhamanan, Saiful Haq, et al. 2023. “DSPy: Compiling Declarative Language Model Calls into Self-Improving Pipelines.” arXiv Preprint arXiv:2310.03714. https://arxiv.org/abs/2310.03714.

Kim, Edward S., Roy S. Herbst, Ignacio I. Wistuba, J. Jack Lee, George R. Blumenschein, Anne Tsao, David J. Stewart, et al. 2011. “The BATTLE Trial: Personalizing Therapy for Lung Cancer.” Cancer Discovery 1 (1): 44–53. https://doi.org/10.1158/2159-8274.CD-10-0010.

King, Andrew J., Lisa Higgins, Carly Au, Salim Malakouti, Edvin Music, Kyle Kalchthaler, et al. 2024. “Automatic Population of the Case Report Forms for an International Multifactorial Adaptive Platform Trial Amid the COVID-19 Pandemic.” AMIA Joint Summits on Translational Science Proceedings 2024: 276–84. https://pmc.ncbi.nlm.nih.gov/articles/PMC11141839/.

Korn, Edward L., and Boris Freidlin. 2011. “Outcome-Adaptive Randomization: Is It Useful?” Journal of Clinical Oncology 29 (6): 771–76. https://doi.org/10.1200/JCO.2010.31.1423.

Krams, Michael, Kennedy R. Lees, Werner Hacke, Andrew P. Grieve, Jean-Marc Orgogozo, and Gary A. Ford. 2003. “Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): An Adaptive Dose-Response Study of UK-279,276 in Acute Ischemic Stroke.” Stroke 34 (11): 2543–48. https://doi.org/10.1161/01.STR.0000092527.33910.89.

Lamberti, Mary Jo, Abigail Dirks, Nicholas Kikuchi, Neha Patel Cervantes, and Kenneth Getz. 2024. “Benchmarking Site Activation and Patient Enrollment.” Therapeutic Innovation & Regulatory Science 58 (4): 696–703. https://doi.org/10.1007/s43441-024-00638-1.

Lan, K. K. Gordon, and David L. DeMets. 1983. “Discrete Sequential Boundaries for Clinical Trials.” Biometrika 70 (3): 659–63. https://doi.org/10.1093/biomet/70.3.659.

Landgren, Ola, and Sean M. Devlin. 2025. “Minimal Residual Disease as an Early Endpoint for Accelerated Drug Approval in Myeloma: A Roadmap.” Blood Cancer Discovery 6 (1): 13–22. https://doi.org/10.1158/2643-3230.BCD-24-0292.

Laranjo, Liliana, Adam G. Dunn, Huong Ly Tong, A. Baki Kocaballi, Jessica Chen, Rabia Bashir, Didi Surian, et al. 2018. “Conversational Agents in Healthcare: A Systematic Review.” Journal of the American Medical Informatics Association 25 (9): 1248–58. https://pmc.ncbi.nlm.nih.gov/articles/PMC6118869/.

Laubenbacher, Reinhard, James P. Sluka, and James A. Glazier. 2021. “Using Digital Twins in Viral Infection.” Science 371 (6534): 1105–6. https://doi.org/10.1126/science.abf3370.

Lavori, Philip W., and Ree Dawson. 2000. “A Design for Testing Clinical Strategies: Biased Adaptive Within-Subject Randomization.” Journal of the Royal Statistical Society: Series A (Statistics in Society) 163 (1): 29–38. https://doi.org/10.1111/1467-985X.00154.

Le Tourneau, Christophe, J. Jack Lee, and Lillian L. Siu. 2009. “Dose Escalation Methods in Phase i Cancer Clinical Trials.” Journal of the National Cancer Institute 101 (10): 708–20. https://doi.org/10.1093/jnci/djp079.

Lewis, Patrick, Ethan Perez, Aleksandra Piktus, Fabio Petroni, Vladimir Karpukhin, Naman Goyal, Heinrich Küttler, et al. 2020. “Retrieval-Augmented Generation for Knowledge-Intensive NLP Tasks.” Advances in Neural Information Processing Systems 33: 9459–74. https://arxiv.org/abs/2005.11401.

Lin, Ruitao, and Guosheng Yin. 2017. “Bayesian Optimal Interval Design for Dose Finding in Drug-Combination Trials.” Statistical Methods in Medical Research 26 (5): 2155–67. https://doi.org/10.1177/0962280215594494.

Lin, Yunzhi, Mumu Zhu, and Zheng Su. 2015. “The Pursuit of Balance: An Overview of Covariate-Adaptive Randomization Techniques in Clinical Trials.” Contemporary Clinical Trials 45: 21–25. https://doi.org/10.1016/j.cct.2015.07.011.

Lipsitch, Marc, Eric Tchetgen Tchetgen, and Ted Cohen. 2010. “Negative Controls: A Tool for Detecting Confounding and Bias in Observational Studies.” Epidemiology 21 (3): 383–88. https://doi.org/10.1097/EDE.0b013e3181d61eeb.

Liu, Suyu, and Ying Yuan. 2015. “Bayesian Optimal Interval Designs for Phase I Clinical Trials.” Journal of the Royal Statistical Society: Series C (Applied Statistics) 64 (3): 507–23. https://doi.org/10.1111/rssc.12089.

Liu, Xiaoxuan et al. 2020. “CONSORT-AI Extension: Reporting Guidelines for Clinical Trials Evaluating Artificial Intelligence Interventions.” BMJ 370: m3164. https://www.bmj.com/content/370/bmj.m3164.

Lopez Bernal, Jamie, Nick Andrews, Charlotte Gower, Eileen Gallagher, Ruth Simmons, Simon Thelwall, Julia Stowe, et al. 2021. “Effectiveness of Covid-19 Vaccines Against the B.1.617.2 (Delta) Variant.” New England Journal of Medicine 385 (7): 585–94. https://doi.org/10.1056/NEJMoa2108891.

Ma, Wei, Ping Li, Li-Xin Zhang, and Feifang Hu. 2024. “A New and Unified Family of Covariate Adaptive Randomization Procedures and Their Properties.” Journal of the American Statistical Association 119 (545): 151–62. https://doi.org/10.1080/01621459.2022.2102986.

MacDougall, James. 2006. “Analysis of Dose-Response Studies: Emax Model.” In Dose Finding in Drug Development, edited by Naitee Ting, 127–45. Springer. https://doi.org/10.1007/0-387-33706-7_9.

Mandel, Joshua C., David A. Kreda, Kenneth D. Mandl, Isaac S. Kohane, and Rachel B. Ramoni. 2016. “SMART on FHIR: A Standards-Based, Interoperable Apps Platform for Electronic Health Records.” Journal of the American Medical Informatics Association 23 (5): 899–908. https://pmc.ncbi.nlm.nih.gov/articles/PMC4997036/.

Mander, Adrian P., and Michael J. Sweeting. 2015. “A Product of Independent Beta Probabilities Dose Escalation Design for Dual-Agent Phase I Trials.” Statistics in Medicine 34 (8): 1261–76. https://doi.org/10.1002/sim.6434.

Marion, Joe, Elizabeth Lorenzi, Cora Allen-Savietta, Scott Berry, and Kert Viele. 2025. “Predictive Probabilities Made Simple: A Fast and Accurate Method for Clinical Trial Decision-Making.” Statistics in Medicine 44 (13-14): e70120. https://doi.org/10.1002/sim.70120.

MarketsandMarkets. 2024. “Electronic Trial Master File System Market.” https://www.marketsandmarkets.com/Market-Reports/electronic-trial-master-file-system-market-94357456.html.

Medable. 2024a. “Medable Releases New AI Agent to Automate Trial Master File Processing.” https://www.biopharmatrend.com/news/medable-releases-new-ai-agent-to-automate-trial-master-file-processing-1447/.

———. 2024b. “Medable: Decentralized Clinical Trial Platform.” https://www.medable.com.

———. 2026. “Medable Clinical Trial Platform.” https://www.medable.com.

Medicenna Therapeutics Corp. 2020. “Medicenna Provides MDNA55 rGBM Clinical Program Update Following Positive End of Phase 2 Meeting with the U.S. Food and Drug Administration (FDA).” Press release, October 15, 2020. https://ir.medicenna.com/news-releases/news-release-details/medicenna-provides-mdna55-rgbm-clinical-program-update-following/.

Medicines and Healthcare products Regulatory Agency. 2025. “MHRA Draft Guideline on the Use of External Control Arms Based on Real-World Data to Support Regulatory Decisions.” https://www.gov.uk/government/consultations/mhra-draft-guideline-on-the-use-of-external-control-arms-based-on-real-world-data-to-support-regulatory-decisions.

Medidata Solutions. 2020. “Medidata Synthetic Control Arm Supported by the US Food and Drug Administration (FDA) for Use in Medicenna Therapeutics, Corp. Phase 3 Registrational Trial in Recurrent Glioblastoma.” Press release (Business Wire), October 28, 2020. https://www.businesswire.com/news/home/20201028005277/en/Medidata-Synthetic-Control-Arm-Supported-by-the-US-Food-and-Drug-Administration-FDA-for-Use-in-Medicenna-Therapeutics-Corp.-Phase-3-Registrational-Trial-in-Recurrent-Glioblastoma.

———. 2024a. “Everest Group EDC PEAK Matrix Assessment.” https://www.medidata.com/en/everest-group-edc-peak-matrix/.

———. 2024b. “Medidata Rave EDC.” https://www.medidata.com/en/clinical-trial-products/clinical-data-management/edc-systems.

———. 2024c. “Medidata Sensor Cloud: Wearable Sensors.” https://www.medidata.com/en/patient-experience/wearable-sensors/.

———. 2024d. “Medidata Synthetic Control Arm.” https://medidata.com/en/clinical-trial-products/medidata-ai/real-world-data/synthetic-control-arm.

Medpace Holdings, Inc. 2026. “Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Results.” https://investor.medpace.com/news-releases/news-release-details/medpace-holdings-inc-reports-fourth-quarter-and-full-year-2025/.

Mehta, Cyrus R., and Stuart J. Pocock. 2011. “Adaptive Increase in Sample Size When Interim Results Are Promising: A Practical Guide with Examples.” Statistics in Medicine 30 (28): 3267–84. https://doi.org/10.1002/sim.4102.

Mei, Kai, Xi Zhu, Wujiang Xu, Wenyue Hua, Mingyu Jin, Zelong Li, Shuyuan Xu, Ruosong Ye, Yingqiang Ge, and Yongfeng Zhang. 2024. “AIOS: LLM Agent Operating System.” arXiv Preprint arXiv:2403.16971. https://arxiv.org/abs/2403.16971.

Meinert, Curtis L. 2013. Clinical Trials Handbook: Design and Conduct. Hoboken, NJ: John Wiley & Sons.

Mello, Michelle M., Brian R. Clarridge, and David M. Studdert. 2005. “Academic Medical Centers’ Standards for Clinical-Trial Agreements with Industry.” New England Journal of Medicine 352 (21): 2202–10. https://doi.org/10.1056/NEJMsa044115.

Messeri, Lisa, and M. J. Crockett. 2024. “Artificial Intelligence and Illusions of Understanding in Scientific Research.” Nature. https://www.nature.com/articles/s41586-024-07146-0.

Ministry of Health, Labour and Welfare. 2024. “Revision of Notification on Handling of Submission of Electronic Study Data for New Drug Applications.” https://www.pmda.go.jp/files/000267942.pdf.

Mitchell, Margaret, Simone Wu, Andrew Zaldivar, Parker Barnes, Lucy Vasserman, Ben Hutchinson, Elena Spitzer, Inioluwa Deborah Raji, and Timnit Gebru. 2019. “Model Cards for Model Reporting.” In Proceedings of the Conference on Fairness, Accountability, and Transparency, 220–29. https://doi.org/10.1145/3287560.3287596.

Moore, Thomas J., Hanzhe Zhang, Gerard Anderson, and G. Caleb Alexander. 2018. “Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016.” JAMA Internal Medicine 178 (11): 1451–57. https://doi.org/10.1001/jamainternmed.2018.3931.

Murphy, Susan A. 2005. “An Experimental Design for the Development of Adaptive Treatment Strategies.” Statistics in Medicine 24 (10): 1455–81. https://doi.org/10.1002/sim.2022.

Muss, Hyman B., Donald A. Berry, Constance T. Cirrincione, Maria Theodoulou, Ann M. Mauer, Alice B. Kornblith, Ann H. Partridge, et al. 2009. “Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer.” New England Journal of Medicine 360 (20): 2055–65. https://doi.org/10.1056/NEJMoa0810266.

Nahum-Shani, Inbal, Ashkan Ertefaie, Xi Lu, Kevin G. Lynch, James R. McKay, David W. Oslin, and Daniel Almirall. 2017. “A SMART Data Analysis Method for Constructing Adaptive Treatment Strategies for Substance Use Disorders.” Addiction 112 (5): 901–9. https://doi.org/10.1111/add.13743.

National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. 1979. “The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research.” https://www.hhs.gov/ohrp/regulations-and-policy/belmont-report/read-the-belmont-report/index.html.

National Institute for Health and Care Excellence. 2022. “NICE Technology Appraisal and Highly Specialised Technologies Guidance: The Manual.” https://www.nice.org.uk/process/pmg36.

National Institute of Standards and Technology. 2023. “Artificial Intelligence Risk Management Framework (AI RMF 1.0).” https://www.nist.gov/itl/ai-risk-management-framework.

National Institutes of Health. 2023. “NIH Policy for Data Management and Sharing.” https://sharing.nih.gov/data-management-and-sharing-policy/about-data-management-and-sharing-policies.

National Library of Medicine. 2024. “NIH Common Data Elements (CDE) Repository.” https://cde.nlm.nih.gov/.

Neuenschwander, Beat, Michael Branson, and Thomas Gsponer. 2008. “Critical Aspects of the Bayesian Approach to Phase I Cancer Trials.” Statistics in Medicine 27 (13): 2420–39. https://doi.org/10.1002/sim.3230.

Neuenschwander, Beat, Gorana Capkun-Niggli, Michael Branson, and David J. Spiegelhalter. 2010. “Summarizing Historical Information on Controls in Clinical Trials.” Clinical Trials 7 (1): 5–18. https://doi.org/10.1177/1740774509356002.

NextTrial. 2024. “NextTrial AI: Clinical Trial Intelligence.” https://www.nexttrial.ai.

Nuremberg Military Tribunal. 1949. “The Nuremberg Code.” https://collections.nlm.nih.gov/catalog/nlm:nlmuid-01130400RX2-mvpart.

O’Brien, Peter C., and Thomas R. Fleming. 1979. “A Multiple Testing Procedure for Clinical Trials.” Biometrics 35 (3): 549–56. https://doi.org/10.2307/2530245.

O’Hagan, Anthony, John W. Stevens, and Michael J. Campbell. 2005. “Assurance in Clinical Trial Design.” Pharmaceutical Statistics 4 (3): 187–201. https://doi.org/10.1002/pst.175.

O’Quigley, John, Margaret Pepe, and Lloyd Fisher. 1990. “Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer.” Biometrics 46 (1): 33–48. https://doi.org/10.2307/2531628.

Obermeyer, Ziad, Brian Powers, Christine Vogeli, and Sendhil Mullainathan. 2019. “Dissecting Racial Bias in an Algorithm Used to Manage the Health of Populations.” Science 366 (6464): 447–53. https://doi.org/10.1126/science.aax2342.

Octozi. 2024. “Octozi: AI for Clinical Operations.” https://www.octozi.com.

Ogier du Terrail, Jean, Quentin Klopfenstein, Honghao Li, Imke Mayer, Nicolas Loiseau, Mohammad Hallal, Michael Debouver, Thibault Camalon, et al. 2025. “FedECA: Federated External Control Arms for Causal Inference with Time-to-Event Data in Distributed Settings.” Nature Communications 16 (1): 7496. https://doi.org/10.1038/s41467-025-62525-z.

Overhage, J. Marc, Patrick B. Ryan, Christian G. Reich, Abraham G. Hartzema, and Paul E. Stang. 2012. “Validation of a Common Data Model for Active Safety Surveillance Research.” Journal of the American Medical Informatics Association 19 (1): 54–60. https://doi.org/10.1136/amiajnl-2011-000376.

Pallmann, Philip, Alun W. Bedding, Babak Choodari-Oskooei, Munyaradzi Dimairo, Laura Flight, Lisa V. Hampson, Jane Holmes, et al. 2018. “Adaptive Designs in Clinical Trials: Why Use Them, and How to Run and Report Them.” BMC Medicine 16 (1): 29. https://doi.org/10.1186/s12916-018-1017-7.

PANTHER Trial Investigators. 2024. “PANTHER: Precision Medicine Adaptive Network Platform Trial in Hypoxaemic Acute Respiratory Failure.” https://www.panthertrial.org.

Park, John W., Minetta C. Liu, Douglas Yee, Christina Yau, Laura J. van ’t Veer, W. Fraser Symmans, Melissa Paoloni, et al. 2016. “Adaptive Randomization of Neratinib in Early Breast Cancer.” New England Journal of Medicine 375 (1): 11–22. https://doi.org/10.1056/NEJMoa1513750.

Park, Joon Sung, Joseph C. O’Brien, Carrie J. Cai, Meredith Ringel Morris, Percy Liang, and Michael S. Bernstein. 2023. “Generative Agents: Interactive Simulacra of Human Behavior.” In Proceedings of the 36th Annual ACM Symposium on User Interface Software and Technology (UIST ’23). https://doi.org/10.1145/3586183.3606763.

PCORnet. 2025. “PCORnet Common Data Model (CDM) Specification, Version 7.0.” https://pcornet.org/wp-content/uploads/2025/05/PCORnet_Common_Data_Model_v70_2025_05_01.pdf.

Pearl, Judea. 2009. Causality: Models, Reasoning, and Inference. 2nd ed. Cambridge: Cambridge University Press.

Pelham, William E., Gregory A. Fabiano, James G. Waxmonsky, Andrew R. Greiner, Elizabeth M. Gnagy, et al. 2016. “Treatment Sequencing for Childhood ADHD: A Multiple-Randomization Study of Adaptive Medication and Behavioral Interventions.” Journal of Clinical Child & Adolescent Psychology 45 (4): 396–415. https://doi.org/10.1080/15374416.2015.1105138.

Pharmaceutical Research and Manufacturers of America. 2024. “The Economic Impact of the u.s. Biopharmaceutical Industry.” https://phrma.org/resource-center/topics/economic-impact/industry-economic-impact.

Phlexglobal. 2024. “Phlexglobal eTMF Software.” https://www.phlexglobal.com/etmf-software.

Pocock, Stuart J. 1977. “Group Sequential Methods in the Design and Analysis of Clinical Trials.” Biometrika 64 (2): 191–99. https://doi.org/10.1093/biomet/64.2.191.

Pocock, Stuart J., Cono A. Ariti, Timothy J. Collier, and Duolao Wang. 2012. “The Win Ratio: A New Approach to the Analysis of Composite Endpoints in Clinical Trials Based on Clinical Priorities.” European Heart Journal 33 (2): 176–82. https://doi.org/10.1093/eurheartj/ehr352.

Pocock, Stuart J., and Richard Simon. 1975. “Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial.” Biometrics 31 (1): 103–15. https://doi.org/10.2307/2529712.

Pokorney, Sean D., Noelle Cocoros, Hussein R. Al-Khalidi, Kevin Haynes, Shuang Li, Sana M. Al-Khatib, et al. 2022. “Effect of Mailing Educational Material to Patients with Atrial Fibrillation and Their Clinicians on Use of Oral Anticoagulants: A Randomized Clinical Trial.” JAMA Network Open 5 (5): e2214321. https://doi.org/10.1001/jamanetworkopen.2022.14321.

Prasad, Vinay, and Sham Mailankody. 2017. “Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.” JAMA Internal Medicine 177 (11): 1569–75. https://doi.org/10.1001/jamainternmed.2017.3601.

Prasad, Vinay, and Martin A. Makary. 2026. “One Pivotal Trial, the New Default Option for FDA Approval: Ending the Two-Trial Dogma.” New England Journal of Medicine 394 (8): 815–17. https://doi.org/10.1056/NEJMsb2517623.

Proschan, Michael A., and Scott R. Evans. 2020. “Resist the Temptation of Response-Adaptive Randomization.” Clinical Infectious Diseases 71 (11): 3002–4. https://doi.org/10.1093/cid/ciaa334.

Quintana, Melanie, Benjamin R. Saville, Matteo Vestrucci, Michelle A. Detry, Lori Chibnik, Jeremy Shefner, James D. Berry, et al. 2023. “Design and Statistical Innovations in a Platform Trial for Amyotrophic Lateral Sclerosis.” Annals of Neurology 94 (3): 547–60. https://doi.org/10.1002/ana.26714.

Rao, Gowtham A. 2026. “The OHDSI Phenotype Library.” R package and GitHub repository, version 3.37.0, part of HADES. https://github.com/OHDSI/PhenotypeLibrary.

RECOVERY Collaborative Group, Peter Horby, Wei Shen Lim, Jonathan R. Emberson, Marion Mafham, Jennifer L. Bell, et al. 2021. “Dexamethasone in Hospitalized Patients with Covid-19.” New England Journal of Medicine 384 (8): 693–704. https://doi.org/10.1056/NEJMoa2021436.

Redman, Mary W., Vassiliki A. Papadimitrakopoulou, Glenwood D. Goss, et al. 2020. “Biomarker-Driven Therapies for Previously Treated Squamous Non-Small-Cell Lung Cancer (Lung-MAP SWOG S1400): A Biomarker-Driven Master Protocol.” The Lancet Oncology 21 (12): 1589–1601. https://doi.org/10.1016/S1470-2045(20)30475-7.

REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, Ewan C. Goligher, Corrinne A. Bradbury, Bryan J. McVerry, et al. 2021. “Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.” New England Journal of Medicine 385 (9): 777–89. https://doi.org/10.1056/NEJMoa2103417.

REMAP-CAP Investigators, Anthony C. Gordon, Paul R. Mouncey, Farah Al-Beidh, Kathryn M. Rowan, Alistair D. Nichol, et al. 2021. “Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.” New England Journal of Medicine 384 (16): 1491–1502. https://doi.org/10.1056/NEJMoa2100433.

Renfro, Lindsay A., and Daniel J. Sargent. 2017. “Statistical Controversies in Clinical Research: Basket Trials, Umbrella Trials, and Other Master Protocols: A Review and Examples.” Annals of Oncology 28 (1): 34–43. https://doi.org/10.1093/annonc/mdw413.

Ritchie, Craig W., José Luis Molinuevo, Luc Truyen, Andrew Satlin, Serge Van der Geyten, Simon Lovestone, and EPAD Consortium. 2016. “Development of Interventions for the Secondary Prevention of Alzheimer’s Dementia: The European Prevention of Alzheimer’s Dementia (EPAD) Project.” Lancet Psychiatry 3 (2): 179–86. https://doi.org/10.1016/S2215-0366(15)00454-X.

Rivera, Samantha Cruz et al. 2020. “SPIRIT-AI Extension: Guidance for Clinical Trial Protocols for Interventions Involving Artificial Intelligence.” BMJ 370: m3210. https://www.bmj.com/content/370/bmj.m3210.

Robins, James M., Miguel A. Hernán, and Babette Brumback. 2000. “Marginal Structural Models and Causal Inference in Epidemiology.” Epidemiology 11 (5): 550–60. https://doi.org/10.1097/00001648-200009000-00011.

Rosenbaum, Paul R., and Donald B. Rubin. 1983. “The Central Role of the Propensity Score in Observational Studies for Causal Effects.” Biometrika 70 (1): 41–55. https://doi.org/10.1093/biomet/70.1.41.

Rosenberger, William F., and John M. Lachin. 2016. Randomization in Clinical Trials: Theory and Practice. 2nd ed. Hoboken, NJ: John Wiley & Sons.

Ross, Jessica L., Arman Sabbaghi, Run Zhuang, and Daniele Bertolini. 2024. “Enhancing Longitudinal Clinical Trial Efficiency with Digital Twins and Prognostic Covariate-Adjusted Mixed Models for Repeated Measures (PROCOVA-MMRM).” arXiv Preprint arXiv:2404.17576. https://arxiv.org/abs/2404.17576.

Rossouw, Jacques E., Garnet L. Anderson, Ross L. Prentice, Andrea Z. LaCroix, Charles Kooperberg, Marcia L. Stefanick, Rebecca D. Jackson, et al. 2002. “Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results from the Women’s Health Initiative Randomized Controlled Trial.” JAMA 288 (3): 321–33. https://doi.org/10.1001/jama.288.3.321.

Roth, Jonathan. 2022. “Pretest with Caution: Event-Study Estimates After Testing for Parallel Trends.” American Economic Review: Insights 4 (3): 305–22. https://doi.org/10.1257/aeri.20210236.

Rubin, Donald B. 1974. “Estimating Causal Effects of Treatments in Randomized and Nonrandomized Studies.” Journal of Educational Psychology 66 (5): 688–701. https://doi.org/10.1037/h0037350.

———. 1987. Multiple Imputation for Nonresponse in Surveys. New York: John Wiley & Sons. https://doi.org/10.1002/9780470316696.

Rush, A. John, Maurizio Fava, Stephen R. Wisniewski, Philip W. Lavori, Madhukar H. Trivedi, Harold A. Sackeim, Michael E. Thase, et al. 2004. “Sequenced Treatment Alternatives to Relieve Depression (STAR*D): Rationale and Design.” Controlled Clinical Trials 25 (1): 119–42. https://doi.org/10.1016/S0197-2456(03)00112-0.

Rush, A. John, Madhukar H. Trivedi, Stephen R. Wisniewski, Andrew A. Nierenberg, Jonathan W. Stewart, Diane Warden, George Niederehe, et al. 2006. “Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*d Report.” American Journal of Psychiatry 163 (11): 1905–17. https://doi.org/10.1176/ajp.2006.163.11.1905.

Ryan, Patrick B. 2024. “OHDSI for Real World Evidence (RWE).” Presentation slides, Observational Health Data Sciences and Informatics. https://www.ohdsi.org/wp-content/uploads/2024/12/2.-OHDSI-for-Real-World-Evidence-RWE-Patrick-Ryan.pdf.

Saama Technologies. 2024. “Saama: Life Sciences Analytics Cloud.” https://www.saama.com.

Saleiro, Pedro, Benedict Kuester, Loren Hinkson, Jesse London, Abby Stevens, Ari Anisfeld, Kit T. Rodolfa, and Rayid Ghani. 2018. “Aequitas: A Bias and Fairness Audit Toolkit.” arXiv Preprint arXiv:1811.05577. https://arxiv.org/abs/1811.05577.

Saunders, Stina, Sarah Gregory, Matthew H. S. Clement, Cindy Birck, Serge Van Der Geyten, and Craig W. Ritchie. 2022. “The European Prevention of Alzheimer’s Dementia Programme: An Innovative Medicines Initiative-Funded Partnership to Facilitate Secondary Prevention of Alzheimer’s Disease Dementia.” Frontiers in Neurology 13: 1051543. https://doi.org/10.3389/fneur.2022.1051543.

Saver, Jeffrey L. 2007. “Novel End Point Analytic Techniques and Interpreting Shifts Across the Entire Range of Outcome Scales in Acute Stroke Trials.” Stroke 38 (11): 3055–62. https://doi.org/10.1161/STROKEAHA.107.488536.

Saville, Benjamin R., and Scott M. Berry. 2016. “Efficiencies of Platform Clinical Trials: A Vision of the Future.” Clinical Trials 13 (3): 358–66. https://doi.org/10.1177/1740774515626362.

Schulz, Kenneth F. 1995. “Subverting Randomization in Controlled Trials.” JAMA 274 (18): 1456–58. https://doi.org/10.1001/jama.1995.03530180050029.

Scott, Neil W., Gladys C. McPherson, Craig R. Ramsay, and Marion K. Campbell. 2002. “The Method of Minimization for Allocation to Clinical Trials: A Review.” Controlled Clinical Trials 23 (6): 662–74. https://doi.org/10.1016/S0197-2456(02)00242-8.

Sel, Kaan, Andrea Hawkins-Daarud, Anirban Chaudhuri, Deen Osman, Ahmad Bahai, David Paydarfar, Karen Willcox, Caroline Chung, and Roozbeh Jafari. 2025. “Survey and Perspective on Verification, Validation, and Uncertainty Quantification of Digital Twins for Precision Medicine.” Npj Digital Medicine 8: 40. https://doi.org/10.1038/s41746-025-01447-y.

Sentinel Operations Center. 2025. “An Assessment of the Sentinel System (2022 to 2024).” U.S. Food and Drug Administration. https://www.sentinelinitiative.org/sites/default/files/documents/PDUFA-VII-Sentinel-System-Report_An-Assessment-of-the-Sentinel-System_2022-to-2024.pdf.

Sertkaya, Aylin, Hui-Hsing Wong, Amber Jessup, and Trinidad Beleche. 2016. “Key Cost Drivers of Pharmaceutical Clinical Trials in the United States.” Clinical Trials 13 (2): 117–26. https://doi.org/10.1177/1740774515625964.

Shiryaev, Albert N. 1978. Optimal Stopping Rules. Berlin: Springer-Verlag.

Shriver, Sharon P., Liora Sahar, Vanhvilai L. Douangchai Wills, Devon V. Adams, and Mark E. Fleury. 2025. “Assessing Populations with Access to National Cancer Institute-Funded Sites Using Local Distance-Based Service Areas.” Journal of Clinical and Translational Science 9 (1): e218. https://doi.org/10.1017/cts.2025.10148.

Simon, Noah, and Richard Simon. 2013. “Adaptive Enrichment Designs for Clinical Trials.” Biostatistics 14 (4): 613–25. https://doi.org/10.1093/biostatistics/kxt010.

Smith, Zachary P., Joseph A. DiMasi, and Kenneth A. Getz. 2024. “New Estimates on the Cost of a Delay Day in Drug Development.” Therapeutic Innovation & Regulatory Science 58 (5): 855–62. https://doi.org/10.1007/s43441-024-00667-w.

Smith, Zachary, Joseph A. DiMasi, and Kenneth A. Getz. 2024. “Quantifying the Value of a Day of Delay in Drug Development.” White Paper. Tufts Center for the Study of Drug Development. https://csdd.tufts.edu/sites/default/files/2025-02/Aug2024%20Day%20of%20Delay%20White%20Paper%20Final.pdf.

Society for Clinical Data Management. 2023. “Database Closure.” Good Clinical Data Management Practices chapter, Journal of the Society for Clinical Data Management. https://scdm.org/wp-content/uploads/2024/07/Database-Closure.pdf.

Sommer, C., D. Zuccolin, V. Arnera, N. Schmitz, P. Adolfsson, N. Colombo, R. Gilg, and B. McDowell. 2018. “Building Clinical Trials Around Patients: Evaluation and Comparison of Decentralized and Conventional Site Models in Patients with Low Back Pain.” Contemporary Clinical Trials Communications 11: 120–26. https://doi.org/10.1016/j.conctc.2018.06.008.

Stein, Charles. 1956. “Inadmissibility of the Usual Estimator for the Mean of a Multivariate Normal Distribution.” In Proceedings of the Third Berkeley Symposium on Mathematical Statistics and Probability, 1:197–206. https://www.degruyter.com/document/doi/10.1525/9780520313880-018/html.

Struebing, Alessandria, Chelsea McKibbon, Haoyao Ruan, Emma Mackay, Natalie Dennis, Russanthy Velummailum, Philip He, et al. 2024. “Augmenting External Control Arms Using Bayesian Borrowing: A Case Study in First-Line Non-Small Cell Lung Cancer.” Journal of Comparative Effectiveness Research 13 (5). https://doi.org/10.57264/cer-2023-0175.

Suissa, Samy. 2008. “Immortal Time Bias in Pharmacoepidemiology.” American Journal of Epidemiology 167 (4): 492–99. https://doi.org/10.1093/aje/kwm324.

Swanson, Chad J., Yong Zhang, Shobha Dhadda, Jianing Wang, June Kaplow, Robert Y. K. Lai, Lars Lannfelt, et al. 2021. “A Randomized, Double-Blind, Phase 2b Proof-of-Concept Clinical Trial in Early Alzheimer’s Disease with Lecanemab, an Anti-aβ Protofibril Antibody.” Alzheimer’s Research and Therapy 13 (1): 80. https://doi.org/10.1186/s13195-021-00813-8.

Taves, Donald R. 1974. “Minimization: A New Method of Assigning Patients to Treatment and Control Groups.” Clinical Pharmacology & Therapeutics 15 (5): 443–53. https://doi.org/10.1002/cpt1974155443.

Thompson, William R. 1933. “On the Likelihood That One Unknown Probability Exceeds Another in View of the Evidence of Two Samples.” Biometrika 25 (3/4): 285–94. https://doi.org/10.2307/2332286.

TMF Reference Model Initiative. 2024. “Trial Master File Reference Model.” https://tmfrefmodel.com/.

Tong, Steven Y. C., Jocelyn Mora, Asha C. Bowen, Matthew P. Cheng, Nick Daneman, Anna L. Goodman, George S. Heriot, et al. 2022. “The Staphylococcus aureus Network Adaptive Platform Trial Protocol: New Tools for an Old Foe.” Clinical Infectious Diseases 75 (11): 2027–34. https://doi.org/10.1093/cid/ciac476.

Tufts Center for the Study of Drug Development. 2013. “89% of Trials Meet Enrollment, but Timelines Slip, Half of Sites Under-Enroll.” Tufts CSDD Impact Report 15(1), January/February 2013. https://csdd.tufts.edu/publications/impact-reports.

———. 2021. “Tufts Center for the Study of Drug Development Impact Reports.” https://csdd.tufts.edu/publications/impact-reports.

———. 2024. “Clinical Trial Management System Benchmarks.” https://csdd.tufts.edu/publications/impact-reports.

UK Collaborative ECMO Trial Group. 1996. “UK Collaborative Randomised Trial of Neonatal Extracorporeal Membrane Oxygenation.” The Lancet 348 (9020): 75–82. https://doi.org/10.1016/S0140-6736(96)04100-1.

Unger, Joseph M., Barbara L. McAneny, and Raymond U. Osarogiagbon. 2025. “Cancer in Rural America: Improving Access to Clinical Trials and Quality of Oncologic Care.” CA: A Cancer Journal for Clinicians 75 (4): 341–61. https://doi.org/10.3322/caac.70006.

Unger, Joseph M., Adrienne Moseley, Beulah Symington, Mariana Chavez-MacGregor, Scott D. Ramsey, and Dawn L. Hershman. 2018. “Geographic Distribution and Survival Outcomes for Rural Patients with Cancer Treated in Clinical Trials.” JAMA Network Open 1 (4): e181235. https://doi.org/10.1001/jamanetworkopen.2018.1235.

United States Congress. 1951. “An Act to Amend Section 503(b) of the Federal Food, Drug, and Cosmetic Act (Durham-Humphrey Amendment).” https://www.govinfo.gov/content/pkg/STATUTE-65/pdf/STATUTE-65-Pg648.pdf.

———. 1997. “Food and Drug Administration Modernization Act of 1997.”

———. 2007. “Food and Drug Administration Amendments Act of 2007 (FDAAA), Public Law 110-85, Section 801.” https://clinicaltrials.gov/policy/fdaaa-801-final-rule.

University of North Carolina at Chapel Hill. 2024. “Nuremberg Code.” https://research.unc.edu/human-research-ethics/resources/ccm3_019064/.

University-Industry Demonstration Partnership. 2014. “Accelerated Clinical Trial Agreement (ACTA).” https://uidp.org/our-work/acta/.

Unlearn.AI. 2024. “Unlearn.AI: Digital Twins for Clinical Trials.” https://www.unlearn.ai.

———. 2025. “A Risk-Based Approach for Leveraging AI in Clinical Trials.” https://www.unlearn.ai/blog/how-unlearn-boosts-trial-power-using-the-fdas-ai-framework.

U.S. Congress. 2022. “Food and Drug Omnibus Reform Act (FDORA) of 2022.” https://www.fda.gov/regulatory-information/selected-amendments-fdc-act/food-and-drug-omnibus-reform-act-fdora-2022.

U.S. Department of Agriculture. 1937. “Report of the Secretary of Agriculture on Deaths Due to Elixir Sulfanilamide-Massengill.”

U.S. Department of Health and Human Services. 2024. “45 CFR Part 46: Protection of Human Subjects (Common Rule).” https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46.

U.S. Environmental Protection Agency. 2007. “Guidance for Preparing Standard Operating Procedures (SOPs) (EPA QA/G-6).” EPA/600/B-07/001. https://www.epa.gov/sites/default/files/2015-06/documents/g6-final.pdf.

U.S. Food and Drug Administration. 1994. “Dose-Response Information to Support Drug Registration.” U.S. Food and Drug Administration. https://www.fda.gov/media/71279/download.

———. 2005. “Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers.” Guidance for Industry, Center for Drug Evaluation and Research. https://www.fda.gov/media/72309/download.

———. 2006. “Guidance for Clinical Trial Sponsors: Establishment and Operation of Clinical Trial Data Monitoring Committees.” https://www.fda.gov/media/75398/download.

———. 2010a. “Adaptive Design Clinical Trials for Drugs and Biologics: Draft Guidance for Industry.” https://web.archive.org/web/2012/http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM201790.pdf.

———. 2010b. “Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials.” U.S. Food and Drug Administration. https://www.fda.gov/media/71512/download.

———. 2013a. “Electronic Source Data in Clinical Investigations: Guidance for Industry.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-source-data-clinical-investigations.

———. 2013b. “Oversight of Clinical Investigations: A Risk-Based Approach to Monitoring.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/oversight-clinical-investigations-risk-based-approach-monitoring.

———. 2014. “Expedited Programs for Serious Conditions – Drugs and Biologics: Guidance for Industry.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expedited-programs-serious-conditions-drugs-and-biologics.

———. 2016. “Use of Electronic Informed Consent in Clinical Investigations: Questions and Answers.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-electronic-informed-consent-clinical-investigations-questions-and-answers.

———. 2018a. “Framework for FDA’s Real-World Evidence Program.” https://www.fda.gov/media/120060/download.

———. 2018b. “The Drug Development Process.” https://www.fda.gov/patients/learn-about-drug-and-device-approvals/drug-development-process.

———. 2018c. “Use of Electronic Health Record Data in Clinical Investigations: Guidance for Industry.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-electronic-health-record-data-clinical-investigations-guidance-industry.

———. 2018d. “Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics.” https://www.fda.gov/media/71195/download.

———. 2019a. “Adaptive Designs for Clinical Trials of Drugs and Biologics: Guidance for Industry.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adaptive-design-clinical-trials-drugs-and-biologics-guidance-industry.

———. 2019b. “Approval Package for Application Number 207103Orig1s008: IBRANCE (Palbociclib).” https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/207103Orig1s008.pdf.

———. 2019c. “Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products.” U.S. Food and Drug Administration. https://www.fda.gov/media/133660/download.

———. 2019d. “Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enrichment-strategies-clinical-trials-support-approval-human-drugs-and-biological-products.

———. 2020. “Compliance Program 7348.811: Clinical Investigators and Sponsor-Investigators.” https://www.fda.gov/media/75927/download.

———. 2021a. “Compliance Program 7348.810: Sponsors and Contract Research Organizations.” https://www.fda.gov/media/75916/download.

———. 2021b. “Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency: Guidance for Industry, Investigators, and Institutional Review Boards.” https://www.fda.gov/media/137496/download.

———. 2021c. “PDUFA Reauthorization Performance Goals and Procedures, Fiscal Years 2023 Through 2027.” https://www.fda.gov/media/151712/download.

———. 2021d. “Project Optimus: Reforming the Dose Optimization and Dose Selection Paradigm in Oncology.” FDA Oncology Center of Excellence. https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus.

———. 2021e. “Providing Regulatory Submissions in Electronic Format: Standardized Study Data. Guidance for Industry.” https://www.fda.gov/media/82716/download.

———. 2022. “Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics.” U.S. Food and Drug Administration. https://www.fda.gov/media/120721/download.

———. 2023a. “21 CFR Part 11: Electronic Records; Electronic Signatures.” https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11.

———. 2023b. “21 CFR Part 50: Protection of Human Subjects.” https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-50.

———. 2023c. “21 CFR Part 56: Institutional Review Boards.” https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-56.

———. 2023d. “Benefit-Risk Assessment for New Drug and Biological Products.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/benefit-risk-assessment-new-drug-and-biological-products.

———. 2023e. “Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-design-and-conduct-externally-controlled-trials-drug-and-biological-products.

———. 2023f. “Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-real-world-data-and-real-world-evidence-support-regulatory-decision-making-drug.

———. 2023g. “Digital Health Technologies for Remote Data Acquisition in Clinical Investigations.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/digital-health-technologies-remote-data-acquisition-clinical-investigations.

———. 2023h. “Digital Health Technologies for Remote Data Acquisition in Clinical Investigations: Guidance for Industry, Investigators, and Other Stakeholders.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/digital-health-technologies-remote-data-acquisition-clinical-investigations.

———. 2023i. “Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments into Endpoints for Regulatory Decision-Making.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-focused-drug-development-incorporating-clinical-outcome-assessments-endpoints-regulatory.

———. 2023j. “Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products: Guidance for Industry.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adjusting-covariates-randomized-clinical-trials-drugs-and-biological-products.

———. 2024a. “21 CFR 312.32: IND Safety Reporting.” https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-B/section-312.32.

———. 2024b. “21 CFR Part 312: Investigational New Drug Application.” https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312.

———. 2024c. “21 CFR Part 54: Financial Disclosure by Clinical Investigators.” https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-54.

———. 2024d. “Clinical Pharmacology Guidance Documents.” https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs.

———. 2024e. “Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies: Guidance for Industry.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diversity-action-plans-improve-enrollment-participants-underrepresented-populations-clinical-studies.

———. 2024f. “Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and Answers.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-systems-electronic-records-and-electronic-signatures-clinical-investigations-questions.

———. 2024g. “FDA Adverse Event Reporting System (FAERS) Public Dashboard.” https://www.fda.gov/drugs/drug-approvals-and-databases/fda-adverse-event-reporting-system-faers-database.

———. 2024h. “FDA Organization.” https://www.fda.gov/about-fda/fda-organization.

———. 2024i. “Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases.” Guidance for Industry, Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. https://www.fda.gov/media/164555/download.

———. 2024j. “Pharmacokinetics in Patients with Impaired Renal Function: Study Design, Data Analysis, and Impact on Dosing. Guidance for Industry.” https://www.fda.gov/media/78573/download.

———. 2024k. “Real-World Data: Assessing Electronic Health Records and Medical Claims Data to Support Regulatory Decision-Making for Drug and Biological Products.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/real-world-data-assessing-electronic-health-records-and-medical-claims-data-support-regulatory.

———. 2024l. “Risk Evaluation and Mitigation Strategies (REMS).” https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems.

———. 2024m. “Study Data Technical Conformance Guide.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/study-data-technical-conformance-guide-technical-specifications-document.

———. 2024n. “Conducting Clinical Trials with Decentralized Elements.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/conducting-clinical-trials-decentralized-elements.

———. 2025a. “CDER/CBER Rare Disease Evidence Principles (RDEP).” https://www.fda.gov/industry/fda-rare-disease-innovation-hub/cdercber-rare-disease-evidence-principles-rdep.

———. 2025b. “Drug Development Tools: Fit-for-Purpose Initiative.” https://www.fda.gov/drugs/development-approval-process-drugs/drug-development-tools-fit-purpose-initiative.

———. 2025c. “Enhancing Participation in Clinical Trials: Eligibility Criteria, Enrollment Practices, and Trial Designs.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enhancing-participation-clinical-trials-eligibility-criteria-enrollment-practices-and-trial-designs.

———. 2025d. “FDA Qualifies Total Hip Bone Mineral Density (BMD) as Surrogate Endpoint for Osteoporosis Drug Development.” https://www.fda.gov/drugs/drug-safety-and-availability/fda-qualifies-total-hip-bone-mineral-density-bmd-surrogate-endpoint-osteoporosis-drug-development.

———. 2025e. “Pediatric Labeling Changes.” https://www.fda.gov/science-research/pediatrics/pediatric-labeling-changes.

———. 2025f. “Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological.

———. 2026a. “Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/demonstrating-substantial-evidence-effectiveness-human-drug-and-biological-products.

———. 2026b. “FDA Launches New Adverse Event Look-Up Tool.” https://www.fda.gov/news-events/press-announcements/fda-launches-new-adverse-event-look-tool.

———. 2026c. “Master Protocols for Drug and Biological Product Development: Guidance for Industry.” https://www.fda.gov/regulatory-information/search-fda-guidance-documents/master-protocols-drug-and-biological-product-development.

———. 2026d. “Prescription Drug User Fee Rates for Fiscal Year 2027.” Federal Register 91 FR 48160, 30 July 2026. https://www.federalregister.gov/documents/2026/07/30/2026-15334/prescription-drug-user-fee-rates-for-fiscal-year-2027.

———. 2026e. “Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products.” U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-bayesian-methodology-clinical-trials-drug-and-biological-products.

U.S. Food and Drug Administration, Oncology Center of Excellence. 2024a. “Project Orbis.” https://www.fda.gov/about-fda/oncology-center-excellence/project-orbis.

———. 2024b. “Real-Time Oncology Review (RTOR).” https://www.fda.gov/about-fda/oncology-center-excellence/real-time-oncology-review.

U.S. Food and Drug Administration, and European Medicines Agency. 2026. “Guiding Principles of Good AI Practice in Drug Development.” https://www.fda.gov/media/189581/download.

U.S. Food and Drug Administration, Health Canada, and UK Medicines and Healthcare products Regulatory Agency. 2021. “Good Machine Learning Practice for Medical Device Development: Guiding Principles.” https://www.fda.gov/medical-devices/software-medical-device-samd/good-machine-learning-practice-medical-device-development-guiding-principles.

US Food and Drug Administration, Center for Biologics Evaluation and Research. 2022. “Clinical Review Memorandum: REBYOTA (Fecal Microbiota, Live-jslm), BLA 125739.” US Food and Drug Administration. https://www.fda.gov/media/164040/download.

VanderWeele, Tyler J., and Peng Ding. 2017. “Sensitivity Analysis in Observational Research: Introducing the E-Value.” Annals of Internal Medicine 167 (4): 268–74. https://doi.org/10.7326/M16-2607.

Veeva Systems. 2024a. “Veeva TMF Intake Agent and Quality Check Agent.” https://www.veeva.com/resources/tmf-intake-agent-and-quality-check-agent/.

———. 2024b. “Veeva Vault Clinical Suite.” https://www.veeva.com/products/vault-clinical/.

———. 2026. “Veeva eTMF.” https://www.veeva.com/products/veeva-etmf/.

Venkatesh, Kaushik P., Marium M. Raza, and Joseph C. Kvedar. 2022. “Health Digital Twins as Tools for Precision Medicine: Considerations for Computation, Implementation, and Regulation.” Npj Digital Medicine 5: 150. https://doi.org/10.1038/s41746-022-00694-7.

Wagner, John, Andrew M. Dahlem, Lynn D. Hudson, Sharon F. Terry, Russ B. Altman, C. Taylor Gilliland, Christopher DeFeo, and Christopher P. Austin. 2018a. “A Dynamic Map for Learning, Communicating, Navigating and Improving Therapeutic Development.” Nature Reviews Drug Discovery 17 (2): 150. https://doi.org/10.1038/nrd.2017.217.

———. 2018b. “Application of a Dynamic Map for Learning, Communicating, Navigating, and Improving Therapeutic Development.” Clinical and Translational Science 11 (2): 166–74. https://doi.org/10.1111/cts.12531.

Wald, Abraham. 1947. Sequential Analysis. New York: John Wiley & Sons.

Wang, Haiyun, and Douglas Yee. 2019. “I-SPY 2: A Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer.” Current Breast Cancer Reports 11 (4): 303–10. https://doi.org/10.1007/s12609-019-00334-2.

Wang, Lei, Chen Ma, Xueyang Feng, Zeyu Zhang, Hao Yang, Jingsen Zhang, Zhiyuan Chen, et al. 2024. “A Survey on Large Language Model Based Autonomous Agents.” Frontiers of Computer Science 18 (6): 186345. https://arxiv.org/abs/2308.11432.

Wang, Zifeng, Junyi Gao, Benjamin Danek, Brandon Theodorou, Ruba Shaik, Shivashankar Thati, Seunghyun Won, and Jimeng Sun. 2025. “Compliance and Factuality of Large Language Models for Clinical Research Document Generation.” Journal of the American Medical Informatics Association. https://doi.org/10.1093/jamia/ocaf174.

Warraich, Haider J., Troy Tazbaz, and Robert M. Califf. 2025. “FDA Perspective on the Regulation of Artificial Intelligence in Health Care and Biomedicine.” JAMA 333 (3): 241–47. https://doi.org/10.1001/jama.2024.21451.

Wasserstein, Ronald L., and Nicole A. Lazar. 2016. “The ASA Statement on p-Values: Context, Process, and Purpose.” The American Statistician 70 (2): 129–33. https://doi.org/10.1080/00031305.2016.1154108.

WCG Clinical. 2024. “2024 Clinical Research Site Challenges Report: Data-Driven Insights on Current Site Challenges and Strategic Recommendations to Overcome Barriers and Boost Clinical Trial Efficiency.” https://www.wcgclinical.com/wp-content/uploads/2024/10/WCG_2024_Clinical_Research_Site_Challenges_Report.pdf.

Wei, Jason, Xuezhi Wang, Dale Schuurmans, Maarten Bosma, Brian Ichter, Fei Xia, Ed Chi, Quoc Le, and Denny Zhou. 2022. “Chain-of-Thought Prompting Elicits Reasoning in Large Language Models.” Advances in Neural Information Processing Systems 35: 24824–37. https://arxiv.org/abs/2201.11903.

Wei, L. J., and S. Durham. 1978. “The Randomized Play-the-Winner Rule in Medical Trials.” Journal of the American Statistical Association 73 (364): 840–43. https://doi.org/10.1080/01621459.1978.10480109.

Wenzl, Martin, and Suzannah Chapman. 2019. “Performance-Based Managed Entry Agreements for New Medicines in OECD Countries and EU Member States: How They Work and Possible Improvements Going Forward.” OECD Health Working Paper 115. Paris: Organisation for Economic Co-operation and Development. https://doi.org/10.1787/6e5e4c0f-en.

WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. 2020. “A Minimal Common Outcome Measure Set for COVID-19 Clinical Research.” Lancet Infectious Diseases 20 (8): e192–97. https://doi.org/10.1016/S1473-3099(20)30483-7.

Wong, Chi Heem, Kien Wei Siah, and Andrew W. Lo. 2019. “Estimation of Clinical Trial Success Rates and Related Parameters.” Biostatistics 20 (2): 273–86. https://doi.org/10.1093/biostatistics/kxx069.

Woodcock, Janet, and Lisa M. LaVange. 2017. “Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both.” New England Journal of Medicine 377 (1): 62–70. https://doi.org/10.1056/NEJMra1510062.

World Health Organization. 2021. “Ethics and Governance of Artificial Intelligence for Health.” https://iris.who.int/handle/10665/341996.

World Medical Association. 2013. “Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects.” https://www.wma.net/policies-post/wma-declaration-of-helsinki/.

———. 2025. “World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Participants.” JAMA 333 (1): 71–74. https://doi.org/10.1001/jama.2024.21972.

Wu, Qingyun, Gagan Bansal, Jieyu Zhang, Yiran Wu, Beibin Li, Erkang Zhu, Li Jiang, et al. 2023. “AutoGen: Enabling Next-Gen LLM Applications via Multi-Agent Conversation.” arXiv Preprint arXiv:2308.08155. https://arxiv.org/abs/2308.08155.

Xu, Yang, Min Dong, and Xuemei Liu. 2020. “Characteristics and Trends of Clinical Studies Primarily Sponsored by China in WHO Primary Registries Between 2009 and 2018: A Cross-Sectional Survey.” BMJ Open 10 (11): e037262. https://doi.org/10.1136/bmjopen-2020-037262.

Yao, Shunyu, Jeffrey Zhao, Dian Yu, Nan Du, Izhak Shafran, Karthik Narasimhan, and Yuan Cao. 2023. “ReAct: Synergizing Reasoning and Acting in Language Models.” International Conference on Learning Representations. https://arxiv.org/abs/2210.03629.

Yuan, Ying, Kenneth R. Hess, Susan G. Hilsenbeck, and Mark R. Gilbert. 2016. “Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.” Clinical Cancer Research 22 (17): 4291–301. https://doi.org/10.1158/1078-0432.CCR-16-0592.

Zhou, Xian, Suyu Liu, Edward S. Kim, Roy S. Herbst, and J. Jack Lee. 2008. “Bayesian Adaptive Design for Targeted Therapy Development in Lung Cancer.” Clinical Trials 5 (3): 181–93. https://doi.org/10.1177/1740774508091815.